Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PTPRB | P23467 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410058 | 1.00 | TDP1 (0.39) | TDP1KDM1AKCNH2KDM1BCYP1A2 | |
| SCHEMBL17295168 | 0.88 | KDM1A (0.34) | KDM1AKCNH2KDM1BCYP1A2CYP2D6 | |
| SCHEMBL1128476 | 0.83 | TAAR1 (0.52) | TDP1CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL29331986 | 0.83 | IGF1R (0.40) | KDM1AKCNH2KDM1BPARP1HTR2A | |
| SCHEMBL4444493 | 0.83 | CYP1A2 (0.46) | TDP1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14555727 | 0.83 | IGF1R (0.40) | KDM1AKCNH2KDM1BPARP1HTR2A | |
| SCHEMBL3120224 | 0.82 | DAO (0.44) | TDP1TAAR1MEN1KMT2ADAO | |
| SCHEMBL377446 | 0.82 | CYP1A2 (0.41) | KDM1AKCNH2KDM1BCYP1A2CYP2D6 | |
| SCHEMBL29447904 | 0.82 | DAO (0.44) | TDP1TAAR1MEN1KMT2ADAO | |
| SCHEMBL8084327 | 0.81 | KDM1A (0.35) | KDM1AKCNH2KDM1BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-116615430-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4211133-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| CN-102066337-A | 5-hydroxypyrimidine-4-carboxamide compounds | DAIICHI SANKYO CO LTD | 2011-05-18 | — | — | CN | disclosed |
| CN-102015728-A | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INT | 2011-04-13 | — | — | CN | disclosed |
| CN-100548986-C | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA INC (CA) | 2009-10-14 | — | — | CN | disclosed |
| CN-101437818-A | Novel Dual Acting Receptor Antagonists (DARA) for AT1 and ETA receptors | TORRENT PHARMACEUTICALS LTD (IN) | 2009-05-20 | — | — | CN | disclosed |
| CN-101379054-A | Piperidine derivatives as CXCR3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-04 | — | — | CN | disclosed |
| CN-1934088-A | As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| CN-1906164-A | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA INC (CA) | 2007-01-31 | — | — | CN | disclosed |
| EP-0563981-B1 | Cis-1,4-substituted 2-butene derivative | CHISSO CORP (JP) | 1997-01-22 | — | — | EP | disclosed |
| US-5401434-A | Cis-1,4-substituted 2-butene derivative | CHISSO CORPORATION (JP) | 1995-03-28 | — | — | US | disclosed |
| EP-0563981-A2 | Cis-1,4-substituted 2-butene derivative | Chisso Corporation (JP) | 1993-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | TDP1 4787/4885KDM1A 2981/4885KCNH2 4252/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | TDP1 4787/4885KDM1A 2981/4885KCNH2 4252/4885 |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TDP1 2650/4885KDM1A 1496/4885KCNH2 1364/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | TDP1 4787/4885KDM1A 2981/4885KCNH2 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.